Enterocin B3A-B3B produced by LAB collected from infant faeces: potential utilization in the food industry for Listeria monocytogenes biofilm management

Antonie Van Leeuwenhoek. 2017 Feb;110(2):205-219. doi: 10.1007/s10482-016-0791-5. Epub 2016 Nov 22.

Abstract

Enterococcus faecalis B3A-B3B produces the bacteriocin B3A-B3B with activity against Listeria monocytogenes, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium perfringens, but apparently not against fungi or Gram-negative bacteria, except for Salmonella Newport. B3A-B3B enterocin has two different nucleotides but similar amino acid composition to the class IIb MR10A-MR10B enterocin. B3A-B3B consists of two peptides of predicted molecular mass of 5176.31 Da (B3A) and 5182.21 Da (B3B). Importantly, B3A-B3B impeded biofilm formation of the foodborne pathogen L. monocytogenes 162 grown on stainless steel. The antimicrobial treatment of stainless steel with nisin (1 or 16 mg ml-1) decreased the cell numbers by about 2 log CFU ml-1, thereby impeding the biofilm formation by L. monocytogenes 162 or its nisin-resistant derivative strain L. monocytogenes 162R. Furthermore, the combination of nisin and B3A-B3B enterocin reduced the MIC required to inhibit this pathogen grown in planktonic or biofilm cultures.

Keywords: Biofilm; Class IIb Enterocin B3A-B3B; Listeria monocytogenes; Nisin; Resistance.

MeSH terms

  • Anti-Bacterial Agents / isolation & purification
  • Anti-Bacterial Agents / pharmacology
  • Biofilms / drug effects*
  • Bridged-Ring Compounds / isolation & purification
  • Bridged-Ring Compounds / pharmacology
  • Enterococcus faecalis / metabolism
  • Feces / microbiology*
  • Food Microbiology*
  • Humans
  • Listeria monocytogenes / drug effects*
  • Microbial Sensitivity Tests
  • Nisin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Bridged-Ring Compounds
  • Nisin
  • enterocin
  • nisin A